The U.S. Department of Defense has recently awarded a notable contract related to the field of chemical, biological, radiological and nuclear (CBRN) equipment or life science research of interest for potential applications in biodefense:
InBios International Inc., Seattle, Washington, was awarded a $9,600,000 cost contract to develop multiple immunochromatographic tests for the rapid diagnosis and detection of infectious diseases and biological warfare agents of military significance.
InBios has previously worked with the U.S. Army on the development of CL Detect™, an FDA-approved hand-held “dipstick” device for the rapid diagnosis of cutaneous leishmaniasis. Additional rapid immunoassays offered by the company include tests for Chagas, Melioidosis, Dengue, Visceral Leishmaniasis, Malaria and Scrub Typhus.
For the current award, the U.S. Army solicited via the Internet with three proposals received. The contract has an estimated completion date of Nov. 30, 2020.
Editor also recommends: NRL Team Works with DTRA to Better Predict Deadly Diseases.
